{"transactions":[{"id":919526,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":1,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-04T21:15:59.000Z","date":"2026-02-02","kind":"purchase","planned":false,"acquired":true,"shares":3184713,"price":1.57,"value":4999999.41,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. The reporting person, a director of venBio Global Strategic GP II, Ltd., disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein."}],"balance_after":8453038,"source":{"system":"sec-edgar","filing":"0001278411-26-000002","document":"form4-02042026_090252.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000127841126000002/form4-02042026_090252.xml","form_type":"4"}},{"id":934339,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":1,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-21T21:30:35.000Z","date":"2026-01-20","kind":"grant","planned":false,"acquired":true,"shares":40400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026."}],"balance_after":40400,"derivative":{"exercise_price":1.32,"expiration_date":"2036-01-19","underlying":"Common Stock","underlying_shares":40400},"source":{"system":"sec-edgar","filing":"0001193125-26-018039","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526018039/ownership.xml","form_type":"4"}},{"id":1296459,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":1,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-23T23:29:17.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":40400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 12 equal monthly installments beginning on February 21, 2025."}],"balance_after":40400,"derivative":{"exercise_price":1.65,"expiration_date":"2035-01-20","underlying":"Common Stock","underlying_shares":40400},"source":{"system":"sec-edgar","filing":"0001415889-25-001979","document":"form4-01232025_110113.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000141588925001979/form4-01232025_110113.xml","form_type":"4"}},{"id":1450564,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Series B Convertible Preferred Stock","published_at":"2024-07-22T20:26:49.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":false,"shares":214692,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":214692},"source":{"system":"sec-edgar","filing":"0000905148-24-001964","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514824001964/form4.xml","form_type":"4"}},{"id":1450563,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-07-22T20:26:49.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":false,"shares":843592,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":843592},"source":{"system":"sec-edgar","filing":"0000905148-24-001964","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514824001964/form4.xml","form_type":"4"}},{"id":1450562,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-22T20:26:49.000Z","date":"2024-07-22","kind":"purchase","planned":false,"acquired":true,"shares":416666,"price":12,"value":4999992.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":1936637,"source":{"system":"sec-edgar","filing":"0000905148-24-001964","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514824001964/form4.xml","form_type":"4"}},{"id":1450561,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-22T20:26:49.000Z","date":"2024-07-22","kind":"other","planned":false,"acquired":true,"shares":461687,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the conversion of outstanding simple agreement for future equity in the amount of approximately $4,709,212 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the $12 IPO price, or $10.20."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the conversion of outstanding simple agreement for future equity in the amount of approximately $4,709,212 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the $12 IPO price, or $10.20."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":1519971,"source":{"system":"sec-edgar","filing":"0000905148-24-001964","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514824001964/form4.xml","form_type":"4"}},{"id":1450560,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-22T20:26:49.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":true,"shares":214692,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":1058284,"source":{"system":"sec-edgar","filing":"0000905148-24-001964","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514824001964/form4.xml","form_type":"4"}},{"id":1450559,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-22T20:26:49.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":true,"shares":843592,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":843592,"source":{"system":"sec-edgar","filing":"0000905148-24-001964","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514824001964/form4.xml","form_type":"4"}},{"id":1479174,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":1,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T20:42:40.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":20200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 12 equal monthly installments on the 13th day of the month, or if earlier, the day immediately before the day of the next annual meeting of stockholders."}],"balance_after":20200,"derivative":{"exercise_price":8.44,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":20200},"source":{"system":"sec-edgar","filing":"0001415889-24-016949","document":"form4-06142024_080636.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000141588924016949/form4-06142024_080636.xml","form_type":"4"}},{"id":1775552,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Series C Convertible Preferred Stock","published_at":"2023-09-21T16:30:01.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":216127,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series C Convertible Preferred Stock (the \"Series C Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-1.14443753806379 basis. Upon the closing of the Issuer's initial public offering, the Series C Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series C Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series C Convertible Preferred Stock (the \"Series C Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-1.14443753806379 basis. Upon the closing of the Issuer's initial public offering, the Series C Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series C Convertible Preferred Stock (the \"Series C Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-1.14443753806379 basis. Upon the closing of the Issuer's initial public offering, the Series C Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series C Convertible Preferred Stock (the \"Series C Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-1.14443753806379 basis. Upon the closing of the Issuer's initial public offering, the Series C Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series C Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":247343},"source":{"system":"sec-edgar","filing":"0000905148-23-000957","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514823000957/form4.xml","form_type":"4"}},{"id":1775551,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Series B Convertible Preferred Stock","published_at":"2023-09-21T16:30:01.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":1123862,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series B Convertible Preferred Stock (the \"Series B Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Convertible Preferred Stock (the \"Series B Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series B Convertible Preferred Stock (the \"Series B Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series B Convertible Preferred Stock (the \"Series B Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1123862},"source":{"system":"sec-edgar","filing":"0000905148-23-000957","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514823000957/form4.xml","form_type":"4"}},{"id":1775550,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Series A Convertible Preferred Stock","published_at":"2023-09-21T16:30:01.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":3786957,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series A Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series A Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series A Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series A Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series A Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series A Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series A Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series A Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3786957},"source":{"system":"sec-edgar","filing":"0000905148-23-000957","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514823000957/form4.xml","form_type":"4"}},{"id":1775549,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-09-21T16:30:01.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":247343,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series C Convertible Preferred Stock (the \"Series C Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-1.14443753806379 basis. Upon the closing of the Issuer's initial public offering, the Series C Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series C Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":5158162,"source":{"system":"sec-edgar","filing":"0000905148-23-000957","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514823000957/form4.xml","form_type":"4"}},{"id":1775548,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-09-21T16:30:01.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":1123862,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Convertible Preferred Stock (the \"Series B Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":4910819,"source":{"system":"sec-edgar","filing":"0000905148-23-000957","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514823000957/form4.xml","form_type":"4"}},{"id":1775547,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-09-21T16:30:01.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":3786957,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series A Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series A Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":3786957,"source":{"system":"sec-edgar","filing":"0000905148-23-000957","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514823000957/form4.xml","form_type":"4"}},{"id":1846614,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":1,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-22T20:32:56.000Z","date":"2023-06-20","kind":"grant","planned":false,"acquired":true,"shares":20200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 12 equal monthly installments on the 20th day of the month, or if earlier, the day immediately before the day of the next annual meeting of stockholders."}],"balance_after":20200,"derivative":{"exercise_price":8.14,"expiration_date":"2033-06-19","underlying":"Common Stock","underlying_shares":20200},"source":{"system":"sec-edgar","filing":"0001209191-23-039082","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919123039082/doc4.xml","form_type":"4"}},{"id":2230117,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":1,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T00:14:20.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":12004,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 12 equal monthly installments on the same day of the month as the grant date, or if earlier, the day immediately before the day of the next annual meeting of stockholders."}],"balance_after":12004,"derivative":{"exercise_price":6.67,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":12004},"source":{"system":"sec-edgar","filing":"0001209191-22-037634","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919122037634/doc4.xml","form_type":"4"}},{"id":2236391,"issuer":{"id":62843,"kind":"organization","name":"Ventyx Biosciences, Inc.","symbol":"VTYX"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T18:22:36.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":13301,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or, (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date the option was granted, in each case, subject to the relevant director (Dr. Royston and Dr. Gaster) continuing to be Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents options awarded to Richard Gaster, a partner of venBio Global Strategic GP III, L.P. (\"venBio GP\"), pursuant to the annual equity grant under the Issuer's non-employee director compensation policy.  These options are held for the benefit of venBio III. Pursuant to policies of venBio Partners, the manager of venBio III, with respect to director compensation, upon the exercise of these options and sale of the underlying securities, the proceeds will be remitted to venBio III. Dr. Gaster disclaims beneficial ownership over the shares underlying the options held for the benefit of venBio III."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"venBio GP is the sole general partner of venBio III. venBio Ltd. is the sole general partner of venBio GP. Dr. Royston, Robert Adelman and Corey Goodman (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the shares held by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the shares underlying the options held for the benefit of venBio III except to the extent of their pecuniary interest therein."}],"balance_after":13301,"derivative":{"exercise_price":16.54,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":13301},"source":{"system":"sec-edgar","filing":"0001567619-22-012695","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000156761922012695/doc1.xml","form_type":"4"}},{"id":2236390,"issuer":{"id":62843,"kind":"organization","name":"Ventyx Biosciences, Inc.","symbol":"VTYX"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T18:22:36.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":13301,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or, (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date the option was granted, in each case, subject to the relevant director (Dr. Royston and Dr. Gaster) continuing to be Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents options awarded to Aaron Royston, a director and partner of venBio Global Strategic GP III, Ltd. (\"venBio Ltd\"), pursuant to the annual equity grant under the Issuer's non-employee director compensation policy.  These options are held for the benefit of venBio Global Strategic Fund III, L.P. (\"venBio III\"). Pursuant to policies of venBio Partners, the manager of venBio III, with respect to director compensation, upon the exercise of these options and sale of the underlying securities, the proceeds will be remitted to venBio III. Dr. Royston disclaims beneficial ownership over the shares underlying the options held for the benefit of venBio III except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"venBio GP is the sole general partner of venBio III. venBio Ltd. is the sole general partner of venBio GP. Dr. Royston, Robert Adelman and Corey Goodman (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the shares held by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the shares underlying the options held for the benefit of venBio III except to the extent of their pecuniary interest therein."}],"balance_after":13301,"derivative":{"exercise_price":16.54,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":13301},"source":{"system":"sec-edgar","filing":"0001567619-22-012695","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000156761922012695/doc1.xml","form_type":"4"}},{"id":2253785,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":3,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":26548,"kind":"person","name":"Royston Aaron","position":5,"cik":"0001727703","reported_name":"Royston Aaron","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2022-05-27T19:20:33.000Z","date":"2022-05-25","kind":"sale","acquired":false,"shares":702737,"price":4.1236,"value":2897806.2932,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.37, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by venBio Global Strategic Fund III, L.P. venBio Global Strategic GP III, L.P. is the sole general partner of venBio Global Strategic Fund III, L.P. and venBio Global Strategic GP III, Ltd. is the sole general partner of venBio Global Strategic GP III, L.P. Each of Corey Goodman, Robert Adelman and Aaron Royston is a director of venBio Global Strategic GP III, Ltd. Each of venBio Global Strategic GP III, L.P., venBio Global Strategic GP III, Ltd, Dr. Goodman, Dr. Adelman and Dr. Royston disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":1905430,"source":{"system":"sec-edgar","filing":"0001140361-22-021085","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000114036122021085/form4.xml","form_type":"4"}},{"id":2267637,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-17T17:12:01.000Z","date":"2022-05-16","kind":"sale","acquired":false,"shares":95800,"price":10.4499,"value":1001100.42,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.44 to $10.45, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2155930,"source":{"system":"sec-edgar","filing":"0001567619-22-011111","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922011111/doc1.xml","form_type":"4"}},{"id":2267636,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-17T17:12:01.000Z","date":"2022-05-13","kind":"sale","acquired":false,"shares":35850,"price":10.4453,"value":374464.005,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.43 to $10.45, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2251730,"source":{"system":"sec-edgar","filing":"0001567619-22-011111","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922011111/doc1.xml","form_type":"4"}},{"id":2273244,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-12T20:47:49.000Z","date":"2022-05-12","kind":"sale","acquired":false,"shares":124525,"price":10.394,"value":1294312.85,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.435, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2287580,"source":{"system":"sec-edgar","filing":"0001567619-22-010353","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922010353/doc1.xml","form_type":"4"}},{"id":2273243,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-12T20:47:49.000Z","date":"2022-05-11","kind":"sale","acquired":false,"shares":17700,"price":10.3752,"value":183641.04,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.45, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2412105,"source":{"system":"sec-edgar","filing":"0001567619-22-010353","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922010353/doc1.xml","form_type":"4"}},{"id":2273242,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-12T20:47:49.000Z","date":"2022-05-10","kind":"sale","acquired":false,"shares":18676,"price":10.3807,"value":193869.9532,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.39, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2429805,"source":{"system":"sec-edgar","filing":"0001567619-22-010353","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922010353/doc1.xml","form_type":"4"}},{"id":2277360,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-09T18:58:28.000Z","date":"2022-05-09","kind":"sale","acquired":false,"shares":17600,"price":10.374,"value":182582.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.38, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2448481,"source":{"system":"sec-edgar","filing":"0001567619-22-009850","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922009850/doc1.xml","form_type":"4"}},{"id":2277359,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-09T18:58:28.000Z","date":"2022-05-06","kind":"sale","acquired":false,"shares":48334,"price":10.3702,"value":501233.2468,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.38, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2466081,"source":{"system":"sec-edgar","filing":"0001567619-22-009850","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922009850/doc1.xml","form_type":"4"}},{"id":2277358,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-09T18:58:28.000Z","date":"2022-05-05","kind":"sale","acquired":false,"shares":20743,"price":10.37,"value":215104.91,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2514415,"source":{"system":"sec-edgar","filing":"0001567619-22-009850","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922009850/doc1.xml","form_type":"4"}},{"id":2281938,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-04T19:30:56.000Z","date":"2022-05-04","kind":"sale","acquired":false,"shares":37500,"price":10.3713,"value":388923.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.38, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2535158,"source":{"system":"sec-edgar","filing":"0001567619-22-009528","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922009528/doc1.xml","form_type":"4"}},{"id":2281937,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-04T19:30:56.000Z","date":"2022-05-03","kind":"sale","acquired":false,"shares":79475,"price":10.3735,"value":824433.9125,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.38, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2572658,"source":{"system":"sec-edgar","filing":"0001567619-22-009528","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922009528/doc1.xml","form_type":"4"}},{"id":2281936,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-04T19:30:56.000Z","date":"2022-05-02","kind":"sale","acquired":false,"shares":153700,"price":10.3837,"value":1595974.69,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.43, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2652133,"source":{"system":"sec-edgar","filing":"0001567619-22-009528","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922009528/doc1.xml","form_type":"4"}},{"id":2287745,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-29T17:50:56.000Z","date":"2022-04-29","kind":"sale","acquired":false,"shares":69230,"price":10.3808,"value":718662.784,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.39, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2805833,"source":{"system":"sec-edgar","filing":"0001567619-22-009203","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922009203/doc1.xml","form_type":"4"}},{"id":2287744,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-29T17:50:56.000Z","date":"2022-04-28","kind":"sale","acquired":false,"shares":73400,"price":10.3806,"value":761936.04,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.40, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2875063,"source":{"system":"sec-edgar","filing":"0001567619-22-009203","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922009203/doc1.xml","form_type":"4"}},{"id":2287743,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-29T17:50:56.000Z","date":"2022-04-27","kind":"sale","acquired":false,"shares":47396,"price":10.3802,"value":491979.9592,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.43, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2948463,"source":{"system":"sec-edgar","filing":"0001567619-22-009203","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922009203/doc1.xml","form_type":"4"}},{"id":2290211,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-26T18:40:39.000Z","date":"2022-04-26","kind":"sale","acquired":false,"shares":64683,"price":10.3823,"value":671558.3109,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.43, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2995859,"source":{"system":"sec-edgar","filing":"0001567619-22-008985","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922008985/doc1.xml","form_type":"4"}},{"id":2290210,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-26T18:40:39.000Z","date":"2022-04-25","kind":"sale","acquired":false,"shares":27668,"price":10.3876,"value":287404.1168,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.43, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":3060542,"source":{"system":"sec-edgar","filing":"0001567619-22-008985","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922008985/doc1.xml","form_type":"4"}},{"id":2290209,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-26T18:40:39.000Z","date":"2022-04-22","kind":"sale","acquired":false,"shares":37430,"price":10.3883,"value":388834.069,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.40, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":3088210,"source":{"system":"sec-edgar","filing":"0001567619-22-008985","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922008985/doc1.xml","form_type":"4"}},{"id":2292593,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-21T20:54:49.000Z","date":"2022-04-21","kind":"sale","acquired":false,"shares":62200,"price":10.3837,"value":645866.14,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.40, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":3125640,"source":{"system":"sec-edgar","filing":"0001567619-22-008823","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922008823/doc1.xml","form_type":"4"}},{"id":2292592,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-21T20:54:49.000Z","date":"2022-04-20","kind":"sale","acquired":false,"shares":85611,"price":10.3887,"value":889386.9957,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.40, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":3187840,"source":{"system":"sec-edgar","filing":"0001567619-22-008823","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922008823/doc1.xml","form_type":"4"}},{"id":2292591,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-21T20:54:49.000Z","date":"2022-04-19","kind":"sale","acquired":false,"shares":399923,"price":10.4151,"value":4165238.0373,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.44, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":3273451,"source":{"system":"sec-edgar","filing":"0001567619-22-008823","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000156761922008823/doc1.xml","form_type":"4"}},{"id":2534629,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":1,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":2,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-26T16:35:03.000Z","date":"2021-10-25","kind":"sale","acquired":false,"shares":540667,"price":1.4907,"value":805972.2969,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.42 to $1.59, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Robert Adelman and Corey Goodman (collectively, the \"Directors\") are each a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd., and the Directors disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2443421,"source":{"system":"sec-edgar","filing":"0001567619-21-018722","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1770835/000156761921018722/doc1.xml","form_type":"4"}},{"id":2534628,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":1,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":2,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-26T16:35:03.000Z","date":"2021-10-22","kind":"sale","acquired":false,"shares":75035,"price":1.6383,"value":122929.8405,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.66, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Robert Adelman and Corey Goodman (collectively, the \"Directors\") are each a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd., and the Directors disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2984088,"source":{"system":"sec-edgar","filing":"0001567619-21-018722","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1770835/000156761921018722/doc1.xml","form_type":"4"}},{"id":2535681,"issuer":{"id":62843,"kind":"organization","name":"Ventyx Biosciences, Inc.","symbol":"VTYX"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series B Preferred Stock","published_at":"2021-10-25T19:40:28.000Z","date":"2021-10-25","kind":"exercise","acquired":false,"shares":395027,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The preferred stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Shares held by venBio III. venBio GP is the sole general partner of venBio III.  venBio Ltd is the sole general partner of venBio GP.  The Directors are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the shares held by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the shares held by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":395027},"source":{"system":"sec-edgar","filing":"0001567619-21-018677","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000156761921018677/doc1.xml","form_type":"4"}},{"id":2535680,"issuer":{"id":62843,"kind":"organization","name":"Ventyx Biosciences, Inc.","symbol":"VTYX"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series A Preferred Stock","published_at":"2021-10-25T19:40:28.000Z","date":"2021-10-25","kind":"exercise","acquired":false,"shares":3289742,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The preferred stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Shares held by venBio III. venBio GP is the sole general partner of venBio III.  venBio Ltd is the sole general partner of venBio GP.  The Directors are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the shares held by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the shares held by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3289742},"source":{"system":"sec-edgar","filing":"0001567619-21-018677","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000156761921018677/doc1.xml","form_type":"4"}},{"id":2535679,"issuer":{"id":62843,"kind":"organization","name":"Ventyx Biosciences, Inc.","symbol":"VTYX"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2021-10-25T19:40:28.000Z","date":"2021-10-25","kind":"purchase","acquired":true,"shares":312500,"price":16,"value":5000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Shares held by venBio III. venBio GP is the sole general partner of venBio III.  venBio Ltd is the sole general partner of venBio GP.  The Directors are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the shares held by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the shares held by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":3997269,"source":{"system":"sec-edgar","filing":"0001567619-21-018677","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000156761921018677/doc1.xml","form_type":"4"}},{"id":2535678,"issuer":{"id":62843,"kind":"organization","name":"Ventyx Biosciences, Inc.","symbol":"VTYX"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2021-10-25T19:40:28.000Z","date":"2021-10-25","kind":"exercise","acquired":true,"shares":3684769,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The preferred stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Shares held by venBio III. venBio GP is the sole general partner of venBio III.  venBio Ltd is the sole general partner of venBio GP.  The Directors are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the shares held by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the shares held by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":3684769,"source":{"system":"sec-edgar","filing":"0001567619-21-018677","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000156761921018677/doc1.xml","form_type":"4"}},{"id":2648099,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":3,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26548,"kind":"person","name":"Royston Aaron","position":5,"cik":"0001727703","reported_name":"Royston Aaron","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-07-01T17:27:53.000Z","date":"2021-06-29","kind":"exercise","acquired":false,"shares":8380034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into approximately 0.236654 shares of the Issuer's common stock immediately prior to the completion of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into approximately 0.236654 shares of the Issuer's common stock immediately prior to the completion of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into approximately 0.236654 shares of the Issuer's common stock immediately prior to the completion of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by venBio Global Strategic Fund III, L.P. venBio Global Strategic GP III, L.P. is the sole general partner of venBio Global Strategic Fund III, L.P. and venBio Global Strategic GP III, Ltd. is the sole general partner of venBio Global Strategic GP III, L.P. Each of Corey Goodman, Robert Adelman and Aaron Royston is a director of venBio Global Strategic GP III, Ltd. Each of venBio Global Strategic GP III, L.P., venBio Global Strategic GP III, Ltd, Dr. Goodman, Dr. Adelman and Dr. Royston disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1983167},"source":{"system":"sec-edgar","filing":"0001567619-21-012858","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000156761921012858/doc1.xml","form_type":"4"}},{"id":2648098,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":3,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26548,"kind":"person","name":"Royston Aaron","position":5,"cik":"0001727703","reported_name":"Royston Aaron","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-01T17:27:53.000Z","date":"2021-06-29","kind":"purchase","acquired":true,"shares":625000,"price":16,"value":10000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by venBio Global Strategic Fund III, L.P. venBio Global Strategic GP III, L.P. is the sole general partner of venBio Global Strategic Fund III, L.P. and venBio Global Strategic GP III, Ltd. is the sole general partner of venBio Global Strategic GP III, L.P. Each of Corey Goodman, Robert Adelman and Aaron Royston is a director of venBio Global Strategic GP III, Ltd. Each of venBio Global Strategic GP III, L.P., venBio Global Strategic GP III, Ltd, Dr. Goodman, Dr. Adelman and Dr. Royston disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2608167,"source":{"system":"sec-edgar","filing":"0001567619-21-012858","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000156761921012858/doc1.xml","form_type":"4"}},{"id":2648097,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":3,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26548,"kind":"person","name":"Royston Aaron","position":5,"cik":"0001727703","reported_name":"Royston Aaron","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-01T17:27:53.000Z","date":"2021-06-29","kind":"exercise","acquired":true,"shares":1983167,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into approximately 0.236654 shares of the Issuer's common stock immediately prior to the completion of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by venBio Global Strategic Fund III, L.P. venBio Global Strategic GP III, L.P. is the sole general partner of venBio Global Strategic Fund III, L.P. and venBio Global Strategic GP III, Ltd. is the sole general partner of venBio Global Strategic GP III, L.P. Each of Corey Goodman, Robert Adelman and Aaron Royston is a director of venBio Global Strategic GP III, Ltd. Each of venBio Global Strategic GP III, L.P., venBio Global Strategic GP III, Ltd, Dr. Goodman, Dr. Adelman and Dr. Royston disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":1983167,"source":{"system":"sec-edgar","filing":"0001567619-21-012858","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000156761921012858/doc1.xml","form_type":"4"}},{"id":2668640,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":1,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-15T22:45:57.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":12004,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 12 equal monthly installments on the same day of the month as the grant date, or if earlier, the day immediately before the day of the next annual meeting of stockholders."}],"balance_after":12004,"derivative":{"exercise_price":59.66,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":12004},"source":{"system":"sec-edgar","filing":"0001209191-21-040722","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919121040722/doc4.xml","form_type":"4"}},{"id":2735787,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"5% Convertible Note due 2021","published_at":"2021-04-29T18:44:07.000Z","date":"2021-04-27","kind":"exercise","acquired":false,"price":0,"reported_value":1359799.28,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest automatically converted into the number of shares of the issuer's common stock shown in Column 7 upon the closing of the issuer's IPO at $13.50 per share (90% of the IPO price)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest automatically converted into the number of shares of the issuer's common stock shown in Column 7 upon the closing of the issuer's IPO at $13.50 per share (90% of the IPO price)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"expiration_date":"2021-12-31","underlying":"Common Stock","underlying_shares":101457},"source":{"system":"sec-edgar","filing":"0000905148-21-000408","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1445499/000090514821000408/form4.xml","form_type":"4"}},{"id":2735786,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"Series C-1 Redeemable Convertible Preferred Stock","published_at":"2021-04-29T18:44:07.000Z","date":"2021-04-27","kind":"exercise","acquired":false,"shares":13233885,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"These shares of the issuer's Series C-1 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These shares of the issuer's Series C-1 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These shares of the issuer's Series C-1 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":808259},"source":{"system":"sec-edgar","filing":"0000905148-21-000408","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1445499/000090514821000408/form4.xml","form_type":"4"}},{"id":2735785,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"Series C-2 Redeemable Convertible Preferred Stock","published_at":"2021-04-29T18:44:07.000Z","date":"2021-04-27","kind":"exercise","acquired":false,"shares":8845942,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"These shares of the issuer's Series C-2 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These shares of the issuer's Series C-2 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These shares of the issuer's Series C-2 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":540265},"source":{"system":"sec-edgar","filing":"0000905148-21-000408","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1445499/000090514821000408/form4.xml","form_type":"4"}},{"id":2735784,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"Series C-3 Redeemable Convertible Preferred Stock","published_at":"2021-04-29T18:44:07.000Z","date":"2021-04-27","kind":"exercise","acquired":false,"shares":8201930,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"These shares of the issuer's Series C-3 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These shares of the issuer's Series C-3 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These shares of the issuer's Series C-3 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":500932},"source":{"system":"sec-edgar","filing":"0000905148-21-000408","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1445499/000090514821000408/form4.xml","form_type":"4"}},{"id":2735783,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"Series D Redeemable Convertible Preferred Stock","published_at":"2021-04-29T18:44:07.000Z","date":"2021-04-27","kind":"exercise","acquired":false,"shares":5876034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These shares of the issuer's Series D redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's initial public offering (\"IPO\"), and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares of the issuer's Series D redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's initial public offering (\"IPO\"), and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares of the issuer's Series D redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's initial public offering (\"IPO\"), and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":358878},"source":{"system":"sec-edgar","filing":"0000905148-21-000408","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1445499/000090514821000408/form4.xml","form_type":"4"}},{"id":2735782,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-04-29T18:44:07.000Z","date":"2021-04-27","kind":"purchase","acquired":true,"shares":450000,"price":15,"value":6750000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2759791,"source":{"system":"sec-edgar","filing":"0000905148-21-000408","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1445499/000090514821000408/form4.xml","form_type":"4"}},{"id":2735781,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-04-29T18:44:07.000Z","date":"2021-04-27","kind":"exercise","acquired":true,"shares":2309791,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the issuer's Series D redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's initial public offering (\"IPO\"), and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares of the issuer's Series C-3 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares of the issuer's Series C-2 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares of the issuer's Series C-1 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest automatically converted into the number of shares of the issuer's common stock shown in Column 7 upon the closing of the issuer's IPO at $13.50 per share (90% of the IPO price)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2309791,"source":{"system":"sec-edgar","filing":"0000905148-21-000408","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445499/000090514821000408/form4.xml","form_type":"4"}},{"id":2739580,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"5% Convertible Note due 2021","published_at":"2021-04-26T19:11:06.000Z","date":"2021-04-22","kind":"other","acquired":true,"price":0,"reported_value":1359799.28,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest will automatically convert into shares of the issuer's common stock shown in column 7 upon the closing of the issuer's initial public offering (the \"IPO\") at $13.50 per share (90% of the IPO price).  The conversion price became fixed upon pricing of the issuer's IPO on April 22, 2021."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest will automatically convert into shares of the issuer's common stock shown in column 7 upon the closing of the issuer's initial public offering (the \"IPO\") at $13.50 per share (90% of the IPO price).  The conversion price became fixed upon pricing of the issuer's IPO on April 22, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest will automatically convert into shares of the issuer's common stock shown in column 7 upon the closing of the issuer's initial public offering (the \"IPO\") at $13.50 per share (90% of the IPO price).  The conversion price became fixed upon pricing of the issuer's IPO on April 22, 2021."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"derivative":{"expiration_date":"2021-12-31","underlying":"Common Stock","underlying_shares":101457},"source":{"system":"sec-edgar","filing":"0000905148-21-000392","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445499/000090514821000392/form4.xml","form_type":"4"}},{"id":3025088,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":1,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":2,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series C Convertible Preferred Stock","published_at":"2020-09-22T17:21:21.000Z","date":"2020-09-18","kind":"exercise","acquired":false,"shares":396089,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Corey Goodman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":396089},"source":{"system":"sec-edgar","filing":"0000905148-20-001037","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1770835/000090514820001037/form4.xml","form_type":"4"}},{"id":3025087,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":1,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":2,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-09-22T17:21:21.000Z","date":"2020-09-18","kind":"exercise","acquired":false,"shares":472250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Corey Goodman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":472250},"source":{"system":"sec-edgar","filing":"0000905148-20-001037","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1770835/000090514820001037/form4.xml","form_type":"4"}},{"id":3025086,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":1,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":2,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-09-22T17:21:21.000Z","date":"2020-09-18","kind":"exercise","acquired":false,"shares":1960784,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Corey Goodman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1960784},"source":{"system":"sec-edgar","filing":"0000905148-20-001037","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1770835/000090514820001037/form4.xml","form_type":"4"}},{"id":3025085,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":1,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":2,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2020-09-22T17:21:21.000Z","date":"2020-09-18","kind":"exercise","acquired":true,"shares":2829123,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Corey Goodman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":3059123,"source":{"system":"sec-edgar","filing":"0000905148-20-001037","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1770835/000090514820001037/form4.xml","form_type":"4"}},{"id":3025084,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":1,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":2,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2020-09-22T17:21:21.000Z","date":"2020-09-18","kind":"purchase","acquired":true,"shares":230000,"price":13,"value":2990000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Corey Goodman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":230000,"source":{"system":"sec-edgar","filing":"0000905148-20-001037","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1770835/000090514820001037/form4.xml","form_type":"4"}},{"id":3059940,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"Series C Preferred Stock","published_at":"2020-08-12T21:00:18.000Z","date":"2020-08-11","kind":"exercise","acquired":false,"shares":3644624,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":487438},"source":{"system":"sec-edgar","filing":"0000905148-20-000880","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000090514820000880/form4.xml","form_type":"4"}},{"id":3059939,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"Series B Preferred Stock","published_at":"2020-08-12T21:00:18.000Z","date":"2020-08-11","kind":"exercise","acquired":false,"shares":8753350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1314165},"source":{"system":"sec-edgar","filing":"0000905148-20-000880","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000090514820000880/form4.xml","form_type":"4"}},{"id":3059938,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"Series A Preferred Stock","published_at":"2020-08-12T21:00:18.000Z","date":"2020-08-11","kind":"exercise","acquired":false,"shares":12500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1671771},"source":{"system":"sec-edgar","filing":"0000905148-20-000880","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000090514820000880/form4.xml","form_type":"4"}},{"id":3059937,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-08-12T21:00:18.000Z","date":"2020-08-11","kind":"purchase","acquired":true,"shares":200000,"price":15,"value":3000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":3673374,"source":{"system":"sec-edgar","filing":"0000905148-20-000880","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000090514820000880/form4.xml","form_type":"4"}},{"id":3059936,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-08-12T21:00:18.000Z","date":"2020-08-11","kind":"exercise","acquired":true,"shares":3473374,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":3473374,"source":{"system":"sec-edgar","filing":"0000905148-20-000880","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278411/000090514820000880/form4.xml","form_type":"4"}},{"id":3078888,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":1,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"Executive Chairman"}}],"security":"Series C Convertible Stock","published_at":"2020-07-22T00:01:50.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":52647,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held of record by Emaldi Corporation for which the reporting person serves as a director. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":52647},"source":{"system":"sec-edgar","filing":"0000899243-20-019911","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019911/doc4.xml","form_type":"4"}},{"id":3078887,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":1,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"Executive Chairman"}}],"security":"Series B Convertible Stock","published_at":"2020-07-22T00:01:50.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":15794,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The shares are held of record by the Goodman Barinaga Trust for which the reporting person serves as trustee."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15794},"source":{"system":"sec-edgar","filing":"0000899243-20-019911","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019911/doc4.xml","form_type":"4"}},{"id":3078886,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":1,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"Executive Chairman"}}],"security":"Series A Convertible Stock","published_at":"2020-07-22T00:01:50.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":78175,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The shares are held of record by the Goodman Barinaga Trust for which the reporting person serves as trustee."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":78175},"source":{"system":"sec-edgar","filing":"0000899243-20-019911","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019911/doc4.xml","form_type":"4"}},{"id":3078885,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":1,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"Executive Chairman"}}],"security":"Series C Convertible Stock","published_at":"2020-07-22T00:01:50.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":1052950,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. The reporting person, a director of venBio Global Strategic GP II, Ltd., disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1052950},"source":{"system":"sec-edgar","filing":"0000899243-20-019911","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019911/doc4.xml","form_type":"4"}},{"id":3078884,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":1,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"Executive Chairman"}}],"security":"Series B Convertible Stock","published_at":"2020-07-22T00:01:50.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":490411,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. The reporting person, a director of venBio Global Strategic GP II, Ltd., disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":490411},"source":{"system":"sec-edgar","filing":"0000899243-20-019911","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019911/doc4.xml","form_type":"4"}},{"id":3078883,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":1,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"Executive Chairman"}}],"security":"Series A Convertible Stock","published_at":"2020-07-22T00:01:50.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":2398588,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. The reporting person, a director of venBio Global Strategic GP II, Ltd., disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2398588},"source":{"system":"sec-edgar","filing":"0000899243-20-019911","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019911/doc4.xml","form_type":"4"}},{"id":3078882,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":1,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"Executive Chairman"}}],"security":"Series A Convertible Stock","published_at":"2020-07-22T00:01:50.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":3100020,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. The reporting person, a director of venBio Global Strategic GP, Ltd., disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3100020},"source":{"system":"sec-edgar","filing":"0000899243-20-019911","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019911/doc4.xml","form_type":"4"}},{"id":3078881,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":1,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"Executive Chairman"}}],"security":"Common Stock","published_at":"2020-07-22T00:01:50.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":52647,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F10","text":"Includes 1,436 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held of record by Emaldi Corporation for which the reporting person serves as a director. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein."}],"balance_after":54083,"source":{"system":"sec-edgar","filing":"0000899243-20-019911","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019911/doc4.xml","form_type":"4"}},{"id":3078880,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":1,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"Executive Chairman"}}],"security":"Common Stock","published_at":"2020-07-22T00:01:50.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":93969,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Includes 19,318 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The shares are held of record by the Goodman Barinaga Trust for which the reporting person serves as trustee."}],"balance_after":113287,"source":{"system":"sec-edgar","filing":"0000899243-20-019911","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019911/doc4.xml","form_type":"4"}},{"id":3078879,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":1,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"Executive Chairman"}}],"security":"Common Stock","published_at":"2020-07-22T00:01:50.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":3941949,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes 476,376 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. The reporting person, a director of venBio Global Strategic GP II, Ltd., disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein."}],"balance_after":5268325,"source":{"system":"sec-edgar","filing":"0000899243-20-019911","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019911/doc4.xml","form_type":"4"}},{"id":3078878,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":1,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"Executive Chairman"}}],"security":"Common Stock","published_at":"2020-07-22T00:01:50.000Z","date":"2020-07-21","kind":"purchase","acquired":true,"shares":850000,"price":19,"value":16150000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. The reporting person, a director of venBio Global Strategic GP II, Ltd., disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein."}],"balance_after":850000,"source":{"system":"sec-edgar","filing":"0000899243-20-019911","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019911/doc4.xml","form_type":"4"}},{"id":3078877,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":1,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"Executive Chairman"}}],"security":"Common Stock","published_at":"2020-07-22T00:01:50.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":3100020,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 869,618 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. The reporting person, a director of venBio Global Strategic GP, Ltd., disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein."}],"balance_after":3969789,"source":{"system":"sec-edgar","filing":"0000899243-20-019911","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019911/doc4.xml","form_type":"4"}},{"id":3080673,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":1,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"Executive Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2020-07-17T23:05:48.000Z","date":"2020-07-16","kind":"grant","acquired":true,"shares":24009,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 36 equal monthly installments beginning on August 16, 2020."}],"balance_after":24009,"derivative":{"exercise_price":19,"expiration_date":"2030-07-16","underlying":"Common Stock","underlying_shares":24009},"source":{"system":"sec-edgar","filing":"0000899243-20-019578","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019578/doc4.xml","form_type":"4"}},{"id":3089014,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-07-06T19:00:36.000Z","date":"2020-07-06","kind":"sale","acquired":false,"shares":4603,"price":33.8304,"value":155721.3312,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $34.07, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3033552,"source":{"system":"sec-edgar","filing":"0000905148-20-000773","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000090514820000773/form4.xml","form_type":"4"}},{"id":3089013,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-07-06T19:00:36.000Z","date":"2020-07-02","kind":"sale","acquired":false,"shares":3800,"price":33.633,"value":127805.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $33.79, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3038155,"source":{"system":"sec-edgar","filing":"0000905148-20-000773","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000090514820000773/form4.xml","form_type":"4"}},{"id":3089012,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-07-06T19:00:36.000Z","date":"2020-07-01","kind":"sale","acquired":false,"shares":108064,"price":34.4519,"value":3723010.1216,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $35.20, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3041955,"source":{"system":"sec-edgar","filing":"0000905148-20-000773","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000090514820000773/form4.xml","form_type":"4"}},{"id":3222863,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-06T17:23:19.000Z","date":"2020-03-06","kind":"sale","acquired":false,"shares":1800,"price":23.7949,"value":42830.82,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.41 to $24.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3150019,"source":{"system":"sec-edgar","filing":"0001012975-20-000291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000291/edgar.xml","form_type":"4"}},{"id":3222862,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-06T17:23:19.000Z","date":"2020-03-05","kind":"sale","acquired":false,"shares":8500,"price":23.5307,"value":200010.95,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.92, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3151819,"source":{"system":"sec-edgar","filing":"0001012975-20-000291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000291/edgar.xml","form_type":"4"}},{"id":3222861,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-06T17:23:19.000Z","date":"2020-03-04","kind":"sale","acquired":false,"shares":35650,"price":23.8083,"value":848765.895,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.86 to $24.12, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3160319,"source":{"system":"sec-edgar","filing":"0001012975-20-000291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000291/edgar.xml","form_type":"4"}},{"id":3233122,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T17:52:57.000Z","date":"2020-03-03","kind":"sale","acquired":false,"shares":6401,"price":22.9962,"value":147198.6762,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $23.49, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The number of shares reported in Column 5 has been reduced by 10,000 to correct a clerical error in the Reporting Person's Form 4 filed on February 12, 2020 and February 27, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3195969,"source":{"system":"sec-edgar","filing":"0001012975-20-000275","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000275/edgar.xml","form_type":"4"}},{"id":3233121,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T17:52:57.000Z","date":"2020-03-02","kind":"sale","acquired":false,"shares":10297,"price":23.061,"value":237459.117,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.08, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The number of shares reported in Column 5 has been reduced by 10,000 to correct a clerical error in the Reporting Person's Form 4 filed on February 12, 2020 and February 27, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3202370,"source":{"system":"sec-edgar","filing":"0001012975-20-000275","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000275/edgar.xml","form_type":"4"}},{"id":3233120,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T17:52:57.000Z","date":"2020-02-28","kind":"sale","acquired":false,"shares":5100,"price":21.3044,"value":108652.44,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.90, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The number of shares reported in Column 5 has been reduced by 10,000 to correct a clerical error in the Reporting Person's Form 4 filed on February 12, 2020 and February 27, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3212667,"source":{"system":"sec-edgar","filing":"0001012975-20-000275","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000275/edgar.xml","form_type":"4"}},{"id":3244064,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-27T19:51:12.000Z","date":"2020-02-27","kind":"sale","acquired":false,"shares":1781,"price":22.54,"value":40143.74,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.40 to $22.74, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3227767,"source":{"system":"sec-edgar","filing":"0001012975-20-000267","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000267/edgar.xml","form_type":"4"}},{"id":3244063,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-27T19:51:12.000Z","date":"2020-02-26","kind":"sale","acquired":false,"shares":2523,"price":22.4397,"value":56615.3631,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.17 to $22.70, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3229548,"source":{"system":"sec-edgar","filing":"0001012975-20-000267","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000267/edgar.xml","form_type":"4"}},{"id":3244062,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-27T19:51:12.000Z","date":"2020-02-25","kind":"sale","acquired":false,"shares":1600,"price":23.6725,"value":37876.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.64 to $24.17, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3232071,"source":{"system":"sec-edgar","filing":"0001012975-20-000267","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000267/edgar.xml","form_type":"4"}},{"id":3277249,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-12T17:56:37.000Z","date":"2020-02-12","kind":"sale","acquired":false,"shares":6,"price":27.14,"value":162.84,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3233671,"source":{"system":"sec-edgar","filing":"0001012975-20-000119","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000119/edgar.xml","form_type":"4"}},{"id":3277248,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-12T17:56:37.000Z","date":"2020-02-11","kind":"sale","acquired":false,"shares":2184,"price":27.0458,"value":59068.0272,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.28, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3233677,"source":{"system":"sec-edgar","filing":"0001012975-20-000119","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000119/edgar.xml","form_type":"4"}},{"id":3277247,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-12T17:56:37.000Z","date":"2020-02-10","kind":"sale","acquired":false,"shares":7836,"price":27.0761,"value":212168.3196,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.18, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3225861,"source":{"system":"sec-edgar","filing":"0001012975-20-000119","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000119/edgar.xml","form_type":"4"}},{"id":3282210,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-10T17:47:40.000Z","date":"2020-02-06","kind":"sale","acquired":false,"shares":6102,"price":27.0329,"value":164954.7558,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.12, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3233697,"source":{"system":"sec-edgar","filing":"0001012975-20-000115","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000115/edgar.xml","form_type":"4"}},{"id":3286656,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-06T16:06:35.000Z","date":"2020-02-05","kind":"sale","acquired":false,"shares":28608,"price":25.9909,"value":743547.6672,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.20 to $26.27, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3239799,"source":{"system":"sec-edgar","filing":"0001012975-20-000113","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000113/edgar.xml","form_type":"4"}},{"id":3286655,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":1,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":2,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":3,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-06T16:06:35.000Z","date":"2020-02-04","kind":"sale","acquired":false,"shares":53731,"price":25.6496,"value":1378178.6576,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.96, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3268407,"source":{"system":"sec-edgar","filing":"0001012975-20-000113","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000101297520000113/edgar.xml","form_type":"4"}}],"next_cursor":"2020-02-06T16:06:35.000000Z,3286655"}